Argos Therapeutics (NASDAQ: ARGS) and Ocera Therapeutics (NASDAQ:OCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Risk & Volatility
Argos Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Ocera Therapeutics has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.
Institutional & Insider Ownership
18.4% of Argos Therapeutics shares are held by institutional investors. Comparatively, 17.7% of Ocera Therapeutics shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by insiders. Comparatively, 7.2% of Ocera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Argos Therapeutics and Ocera Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Argos Therapeutics||$950,000.00||14.80||-$53.02 million||($1.26)||-0.13|
|Ocera Therapeutics||$610,000.00||77.79||-$26.89 million||($0.97)||-1.85|
Ocera Therapeutics has lower revenue, but higher earnings than Argos Therapeutics. Ocera Therapeutics is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and target prices for Argos Therapeutics and Ocera Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Argos Therapeutics presently has a consensus target price of $1.20, indicating a potential upside of 650.00%. Ocera Therapeutics has a consensus target price of $1.92, indicating a potential upside of 7.08%. Given Argos Therapeutics’ higher possible upside, equities analysts plainly believe Argos Therapeutics is more favorable than Ocera Therapeutics.
This table compares Argos Therapeutics and Ocera Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ocera Therapeutics beats Argos Therapeutics on 9 of the 13 factors compared between the two stocks.
About Argos Therapeutics
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
About Ocera Therapeutics
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.